Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

RhoA

  • Home
  • RhoA
Targeting the TRPV4-RhoA-RhoGDI1 Axis: A Novel Approach for Hypertension Therapy
Posted inCardiology Specialties

Targeting the TRPV4-RhoA-RhoGDI1 Axis: A Novel Approach for Hypertension Therapy

Posted by MedXY By MedXY 09/07/2025
A novel inhibitor AH001 targets the TRPV4-RhoA-RhoGDI1 axis to inactivate RhoA signaling, effectively reducing blood pressure and preventing vascular remodeling in hypertensive models, opening new avenues for antihypertensive drug development.
Read More
  • Increased Risk of Pseudophakic Cystoid Macular Edema After Cataract Surgery in Eyes with Prior Pars Plana Vitrectomy: Insights from a Large Retrospective Cohort Study
  • Determinants of One-Year Success in Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study
  • Patient Perceptions of Telehealth Use in Head and Neck Cancer Surveillance: A Qualitative Synthesis
  • Mapping the Gap: Geographic Disparities in Otolaryngologist Availability Versus Patient Demand in the U.S.
  • Acute Colonic Ischemia Following Elective Colectomy for Cancer: Risk Factors, Procedural Associations, and Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in